Ovarian hyperstimulation syndrome: distinction between local and systemic disease

References

• Whelam JG III, Vlahos NF. The ovarian hyper-stimulation syndrome. Fertil Steril 2000;73:883–96
   PubMed Web of Science ®Google Scholar
• Loret de Mola JR., Goldfarb JM, Hecht BR, et al. Gonadotrophins induce higher active renin levels in the follicular fluid of normal and hyperstimulated cycles. Gynecol Endocrinol 1999;13:155–60
   Google Scholar
• Morris RS, Paulson RJ. Increased angiotensin-converting enzyme activity in a patient with severe ovarian hyperstimulation syndrome. Fertil Steril 1999; 71:562–3
   PubMed Web of Science ®Google Scholar
• D'Ambrogio G, Fasciani A, Monti M, et al. Serum vascular endothelial growth factor levels before starting go nadotropin treatment in women who have developed moderate forms of ovarian hyper-stimulation syndrome. Gynecol Endocrinol 1999;13: 311–15
   PubMed Web of Science ®Google Scholar
• Chen CD, Wu MY, Chen HF, et al. Relationships of serum pro-inflammatory cytokines and vascular endothelial growth factor with liver dysfunction in severe ovarian hyperstimulation syndrome. Hum Reprod 2000;15:66–71
   PubMed Web of Science ®Google Scholar
• Delvigne A, Demoulin A, Smitz J, et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I: Clinical and biological features. Hum Reprod 1993;8:1353–60
   PubMed Web of Science ®Google Scholar
• Pellicer A, Albert C, Mercader A et al. The patho-genesis of ovarian hyperstimulation syndrome: in vivo studies investigation of the role of interleukin-1 beta, interleukin-6 and vascular endothelial growth factor. Fertil Steril 1999;71:482–9
   PubMed Web of Science ®Google Scholar
• Aboulghar MA, Mansour RT, Serour GI, et al. Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 1999;87:81–5
   PubMed Web of Science ®Google Scholar
• Kol S, Itskovitz-Eldor J. Severe OHSS: yes, there is a strategy to prevent it Hum Reprod 2000;15:2266–7
   Google Scholar
• Golan A, Ron-el R, Herman A, et al. Ovarian hyper-stimulation syndrome: an update review. Obstet Gynecol Surv 1989;44:430–40
   PubMedGoogle Scholar
• Lyons CA, Wheeler CA, Frishman GN, et al. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod 1994;9:792–9
   PubMed Web of Science ®Google Scholar
• Mathur RS, Akande AV, Keay SD, et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000;73:901–7
   PubMed Web of Science ®Google Scholar
• Buyalos RP, Lee CT. Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertil-ization. Fertil Steril 1996;65:1–10
   PubMed Web of Science ®Google Scholar
• Hughes E, Collins J, Vandekerckhove P. Ovulation induction with urinary follicle stimulating hormone versus human menopausal go nadotropin for do miphene-resistant polycystic ovary syndrome. Cochrane Database Syst Rev 2000;2:CD000087
   Google Scholar
• Enskog A, Henriksson M, Unander M, et al. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyper-stimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999;71:808–14
   PubMed Web of Science ®Google Scholar
• Kligman I, Noyes N, Benadiva CA, et al. Massive deep vein thrombosis in a patient with antithrombin III deficiency undergoing ovarian stimulation for in vitro fertilization. Fertil Steril 1995;63:673–6
   PubMed Web of Science ®Google Scholar
• Rotmensch S, Scommegna A. Spontaneous ovarian hyperstimulation syndrome associated with hypo-thyroidism. Am J Obstet Gynecol 1989;160:1220–2
   PubMed Web of Science ®Google Scholar
• Chen CP, Chen CW, Wang KG. Spontaneous ovarian hyperstimulation syndrome and hyper-prolactinemia in primary hypothyroidism. Acta Obstet Gynecol Scand 1996;75:70–1
   PubMed Web of Science ®Google Scholar
• Cobellis L, Pecori E, De Lucia E, et al. Regression of ovarian enlargement in pharmacological ovulation induction. Gynecol Endocrinol 2001;15:239–42
   PubMed Web of Science ®Google Scholar
• Ohata Y, Harada T, Ito M, et al. Coasting may reduce the severity of the ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome. Gynecol Obstet Invest 2000;50:186–8
   PubMed Web of Science ®Google Scholar
• Al-Inany HG. Human albumin is effective in prevention of severe OHSS. Acta Obstet Gynecol Scand 2001;80:878–82
   PubMed Web of Science ®Google Scholar
• The European Recombinant LH Study Group. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab 2001;86:2607–18
   PubMed Web of Science ®Google Scholar